Indian study finds big drop in antibodies within four months of vaccination

The findings made at Regional Medical Research Centre in Bhubaneswar could help Indian govt decide whether to provide booster doses as some Western countries have done

Vaccination
Healthcare workers inoculate beneficiaries against Covid-19 during a vaccination camp at Shahaji Raje Sport Complex, at Andheri West in Mumbai (Photo: PTI)
Reuters Bhubaneswar
2 min read Last Updated : Sep 14 2021 | 5:43 PM IST
A study of 614 fully vaccinated health workers in India found a "significant" drop in their Covid-fighting antibodies within four months of the first shot.

The findings could help the government decide whether to provide booster doses as some western countries have done.

Waning antibodies do not necessarily mean that immunised people lose their ability to counter the disease, as the body's memory cells may still kick in to offer substantial protection, said the director of a state-run institute that did the study.

"After six months, we should be able to tell you more clearly whether and when a booster would be needed," Sanghamitra Pati of the Regional Medical Research Centre, based in Bhubaneswar, told Reuters on Tuesday.

"And we would urge similar studies in different areas for pan-India data."

British researchers said last month that protection offered by two doses of the Pfizer/BioNTech and the AstraZeneca vaccines begins to fade within six months.

The Indian study, published in the Research Square pre-print platform but yet to be peer reviewed, is one of the first such done in the country involving its main two vaccines - Covishield, a licensed version of the AstraZeneca shot, and domestically developed Covaxin.

Health officials say though they are studying the evolving science on booster doses, the priority is to fully immunise India's 944 million adults. More than 60% of them have received at least one dose and 19% the required two doses.

Covid cases and deaths in India have come down sharply since a peak of more than 400,000 infections in early May. India has reported 33.29 million cases in total and 443,213 deaths.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccine

Next Story